An interventional, randomized, double-blind, placebo-controlled, parallel-assignment, safety /efficacy study for treatment of chronic middle ear infection in adult patients with the antimicrobial peptide OP-145

Submission date	Recruitment status	Prospectively registered
24/09/2007	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
18/01/2008	Completed	Results
Last Edited	Condition category	Individual participant data
18/01/2008	Ear, Nose and Throat	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Nanno F.A.W. Peek

Contact details

Leiden University Medical Center Albinusdreef 2 Leiden Netherlands 2333 ZA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

P02.216

Study information

Scientific Title

Acronym

OP-145

Study objectives

The purpose of this study is to determine the safety, tolerability, and efficacy of OP-145 eardrops to the middle ear of patients with chronic otitis media. We hypothesize that OP-145 will improve the middle ear mucosa in patients with chronic otitis media.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Medical Ethics Committee of the Leiden University Medical Center. Approved on the 19th December 2003 (Ref: P02.216/YR/yr)

Study design

Phase I/II, double-blind, parallel-assignment, safety/efficacy, randomized placebo-controlled trial.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Chronic otitis media

Interventions

Part I dose finding study:

The participants were allocated into four trial arms in the order of inclusion timepoints i.e. the first four participants were allocated to the lowest dose group, second four in the next dose group, etc.

Arm 1: 0.25 mg/ml OP-145 eardrops twice a day Arm 2: 0.5 mg/ml OP-145 eardrops twice a day Arm 3: 1.0 mg/ml OP-145 eardrops twice a day Arm 4: 2.0 mg/ml OP-145 eardrops twice a day

Duration of intervention: 2 weeks

Part II randomised controlled study:

Based on the results of the Part I study the Part II study was executed with 0.5 mg/ml OP-145 eardops twice a day (control: placebo twice a day) for 2 weeks.

Intervention Type

Other

Phase

Phase I/II

Primary outcome measure

Safety of OP-145 eardrops, which will be determined by the following at baseline and week 1, 2, 4, 8, and 12 (for both Part I and II of the trial):

- 1. Hearing levels
- 2. Blood analysis
- 3. Antibody detection
- 4. Bacterial culture of ear and throat swabs
- 5. Quality of life questionnaires (the 36-item Short Form health survey (SF-36), the Brief Illness Perception Questionnaire and the Chronic Ear Survey)

Secondary outcome measures

Efficacy of OP-145 eardrops, assessed by the following at baseline and week 1, 2, 4, 8, and 12:

- 1. Mucosal endoscopic scores (for both Part I and II of the trial)
- 2. Quality of life questionnaires (the 36-item Short Form health survey (SF-36), the Brief Illness Perception Questionnaire and the Chronic Ear Survey) (only for Part II of the trial)

Overall study start date

01/03/2004

Completion date

01/04/2008

Eligibility

Key inclusion criteria

Inclusion criteria for the Part I dose finding study:

- 1. Adults >= 18 years, males and females
- 2. Legally competent, no psychiatric history
- 3. Chronic otitis media with a clear perforation of the tympanic membrane >3 months
- 4. Chronic proliferative mucosal changes (confirmed by Computerised Tomography (CT) scan)
- 5. Antibiotic therapy resistant (Adequately treated with at least 2 different eardrops for >6 weeks)

Inclusion criteria for the Part II randomised controlled study:

- 1. Adults, both males and females, over 18 years of age
- 2. Legally competent, with no history of psychiatric disorders
- 3. Chronic otitis media with a clear perforation of the tympanic membrane, lasting longer than 6 months
- 4. Chronic proliferative mucosal changes (confirmed with CT scan)
- 5. Antibiotic therapy resistant (Adequately treated with at least 2 different eardrops for >6 weeks)

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Part I: 16 patients; Part II: 52, with an interim analysis after 26 patients.

Key exclusion criteria

Exclusion criteria for the Part I dose finding study:

- 1. Presence of cholesteatoma in the treated ear (confirmed with CT-scan)
- 2. History of mastoidectomy in the treated ear (resulting in a 'radicaalholte')
- 3. Pregnant and breastfeeding women
- 4. Patients that have been using topical, oral or parenteral antibiotics or steroids in the last 30 days
- 5. Patients that have been using prednison or any other immunosuppressive agent in the last 30 days
- 6. Patients with serious headaches
- 7. Patients with Down syndrome or other congenital anomalies in the upper respiratory tract
- 8. Immunocompromized patients or patients with auto-immune disorders
- 9. History of seizures
- 10. Patients with deficits at the nervus facialis

Exclusion criteria for the Part II randomised controlled study:

- 1. Presence of cholesteatoma in the treated ear (confirmed with CT-scan)
- 2. History of mastoidectomy in the treated ear (resulting in a 'radicaalholte')
- 3. Pregnant and breastfeeding women
- 4. Patients that have been using topical, oral or parenteral antibiotics or steroids in the last 30 days
- 5. Patients that have been using prednison or any other immunosuppressive agent in the last 30 days
- 6. Patients with serious headaches
- 7. Patients with Down syndrome or other congenital anomalies in the upper respiratory tract
- 8. Immunocompromized patients or patients with auto-immune disorders
- 9. History of seizures
- 10. Patients with deficits at the nervus facialis
- 11. Patients who were included in the Part I dose finding study

Date of first enrolment

01/03/2004

Date of final enrolment

01/04/2008

Locations

Countries of recruitment

Netherlands

Study participating centre Leiden University Medical Center

Leiden Netherlands 2333 ZA

Sponsor information

Organisation

OctoPlus N.V. (The Netherlands)

Sponsor details

c/o Dr Ewoud-Jan van Hoogdalem Zernikedreef 12 Leiden Netherlands 2333 CL

Sponsor type

Industry

Website

http://www.octoplus.nl/index.cfm/site/OctoPlus/pageid/821DEDEC-E30E-0D4E-CC80F8CDD400753F/index.cfm

ROR

https://ror.org/01dn4wg45

Funder(s)

Funder type

Industry

Funder Name

OctoPlus Inc. (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration